Alpha-Synuclein Aggregation Inhibitors

Alpha-Synuclein Aggregation Inhibitors

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Aggregation Inhibitors</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Prasinezumab (PRX002)</td>
<td>α-syn oligomers</td>
</tr>
<tr>
<td class="label">Cinpanemab (BIIB054)</td>
<td>α-syn fibrils</td>
</tr>
<tr>
<td class="label">MEDI1341</td>
<td>α-syn</td>
</tr>
</table>

Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitors represent a promising therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) - collectively known as synucleinopathies. These compounds target the abnormal aggregation of the [alpha-synuclein](/proteins/alpha-synuclein) (alpha-syn) protein, which forms Lewy bodies and contributes to neuronal dysfunction and death. [@parkinsons2020]

Alpha-Synuclein Aggregation Inhibitors

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Alpha-Synuclein Aggregation Inhibitors</th>
</tr>
<tr>
<td class="label">Antibody</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Prasinezumab (PRX002)</td>
<td>α-syn oligomers</td>
</tr>
<tr>
<td class="label">Cinpanemab (BIIB054)</td>
<td>α-syn fibrils</td>
</tr>
<tr>
<td class="label">MEDI1341</td>
<td>α-syn</td>
</tr>
</table>

Alpha Synuclein Aggregation Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

[Alpha-synuclein](/proteins/alpha-synuclein) aggregation inhibitors represent a promising therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA) - collectively known as synucleinopathies. These compounds target the abnormal aggregation of the [alpha-synuclein](/proteins/alpha-synuclein) (alpha-syn) protein, which forms Lewy bodies and contributes to neuronal dysfunction and death. [@parkinsons2020]

The rationale for targeting alpha-syn aggregation stems from: [@pagan2019]

Current therapeutic approaches include: [@athauda2017]

• Small Molecule Inhibitors: Compounds that prevent nucleation and fibril formation
• Antisense Oligonucleotides: Gene therapy approaches to reduce SNCA expression
• Immunotherapies: Active and passive vaccines targeting alpha-syn
• Protein Stabilizers: Compounds that maintain native alpha-syn conformation

Alpha-synuclein (alpha-syn) aggregation inhibitors represent a key therapeutic strategy for Parkinson's disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). These compounds aim to prevent or reverse the pathological aggregation of alpha-syn into Lewy bodies and glial cytoplasmic inclusions^[1]. [@pujols2018]

Pathological Basis

In synucleinopathies, α-syn undergoes a toxic gain-of-function transformation: [@volc2020]

Current therapies target various stages of this aggregation cascade.

Mechanism of Action

Direct Aggregation Inhibitors

Small molecules that bind to α-syn and prevent fibril formation:

• Stabilize monomeric form
• Bind to NACore (residues 61-95) - core aggregation domain
• Prevent β-sheet conformation
• Dissociate existing oligomers

Autophagy Enhancers

Promote clearance of aggregated α-syn:

• [mTOR](/entities/mtor) inhibitors (e.g., rapamycin)
• [TFEB](/proteins/tfeb) activators
• [Autophagy](/entities/autophagy) receptor modulators

Anti-sense Approaches

Reduce α-syn expression:

• ASO therapy targeting SNCA mRNA
• RNAi approaches
• Gene therapy with miRNA delivery

Clinical Candidates

Inosine

Inosine elevates urate, an endogenous antioxidant^[2].

• Mechanism: Antioxidant, 可能 reduces oxidative stress
• Clinical Trials: SURE-PD3 (Phase 3) in PD
• Results: Did not meet primary endpoint

Nilotinib

Nilotinib is a BCR-ABL inhibitor that induces autophagy^[3].

• Mechanism: Autophagy enhancement via c-Abl inhibition
• Clinical Trials: Phase 2 in PD (NCT03254988)
• Results: Showed signals of biological activity

Exenatide

[GLP-1 receptor](/entities/glp1-receptor) agonist with neuroprotective effects^[4].

• Mechanism: Anti-inflammatory, promotes autophagy
• Clinical Trials: Phase 3 in PD (NCT04232969)
• Results: Primary endpoint not met, but post-hoc analysis positive

Anle138b

Anle138b is a small molecule aggregation inhibitor^[5].

• Mechanism: Direct binding to α-syn, inhibits oligomerization
• Development: Phase 1 completed
• Preclinical: Shows rescue in PD models

SynuClean-D

SynuClean-D is a small molecule identified through high-throughput screening^[6].

• Mechanism: Inhibits α-synuclein fibrillation
• Development: Preclinical
• In vivo: Reduces α-syn toxicity in models

Immunotherapy Approaches

Active Immunization

ACI-35 (Affiris) is a liposome-based vaccine targeting phosphorylated α-syn at Ser129^[7].

• Target: pSer129 α-syn
• Phase: Phase 1b/2a completed
• Results: Safe and induced antibody response

Passive Immunization

Gene Therapy Approaches

AAV Vector Delivery

• AAV2-GDNF: Promotes neurotrophic support
• AAV-α-syn antibody: In vivo antibody production
• AAV-SNCA RNAi: Knockdown of α-syn expression

Biomarkers for Target Engagement

• α-synuclein in CSF: Total, oligomeric, phosphorylated forms
• α-syn RT-QuIC: Seed amplification assay
• [Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Marker of neuronal damage
• DaTscan: Dopamine transporter imaging

Disease-Specific Applications

Parkinson's Disease

Primary targets:

• Prevent dopaminergic neuron loss
• Reduce Lewy body formation
• Modulate neuroinflammation

Dementia with Lewy Bodies

Focus on:

• Cortical α-syn pathology
• Cognitive fluctuations
• Visual hallucinations

Multiple System Atrophy

Key considerations:

• Oligodendroglial α-syn pathology
• Autonomic dysfunction
• Rapid progression

Challenges

Combination Strategies

α-syn aggregation inhibitors may combine with:

• Dopaminergic medications
• Neuroprotective agents
• Anti-inflammatory therapies
• Physical/speech therapy

Background

The study of Alpha Synuclein Aggregation Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-pathology)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [DLB](/diseases/dementia-with-lewy-bodies)
• [MSA](/diseases/multiple-system-atrophy)
• [SNCA Gene](/genes/snca)

External Links

• [Alpha-Synuclein Aggregation Inhibitors Clinical Trials](https://clinicaltrials.gov/search?cond=Parkinson+disease&intr=alpha-synuclein+aggregation+inhibitor)
• [Small Molecule Inhibitors - PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=alpha-synuclein+aggregation+inhibitor+small+molecule)
• [Immunotherapy for Synucleinopathies - Lancet Neurology](https://www.thelancet.com/journals/laneur/home)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Targeting Bacterial Curli Fibrils to Prevent α-Synuclein Cross-Seeding](/hypothesis/h-8b7727c1) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: CSGA
• [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
• [Microbial Metabolite-Mediated α-Synuclein Disaggregation](/hypothesis/h-74777459) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: SNCA, HSPA1A, DNMT1
• [APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: MTOR
• [TFEB-PGC1α Mitochondrial-Lysosomal Decoupling](/hypothesis/h-e5a1c16b) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
• [The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction](/hypothesis/h-e3e8407c) — <span style="color:#ffd54f;font-weight:600">0.52</span> · Target: TFEB
• [Enteric Nervous System Prion-Like Propagation Blockade](/hypothesis/h-2e7eb2ea) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TLR4, SNCA
• [Gut Barrier Permeability-α-Synuclein Axis Modulation](/hypothesis/h-6c83282d) — <span style="color:#ffd54f;font-weight:600">0.60</span> · Target: CLDN1, OCLN, ZO1, MLCK

Related Analyses:

• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;